Literature DB >> 19027421

Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination.

Emilio M Dodds1, Gary N Holland, Miles R Stanford, Fei Yu, Willie O Siu, Kayur H Shah, Ninette Ten Dam-van Loon, Cristina Muccioli, Anna Hovakimyan, Talin Barisani-Asenbauer.   

Abstract

PURPOSE: To describe characteristics of intraocular inflammation in eyes with active ocular toxoplasmosis and to identify relationships between signs of inflammation, complications (including elevated intraocular pressure [IOP]), other disease features, and host characteristics.
DESIGN: Multicenter, retrospective, cross-sectional study.
METHODS: We reviewed the medical records of 210 patients with toxoplasmic retinochoroiditis at seven international sites (North America, South America, and Europe) for information from the first examination at each site during which patients had active retinal lesions. Signs of inflammation included anterior chamber (AC) cells and flare and vitreous humor cells and haze. Retinal lesion characteristics included size (< or =1 disc area [DA] or >1 DA) and presence or absence of macular involvement.
RESULTS: AC cells and flare were related to vitreous inflammatory reactions (P < or = .041). One or more signs of increased inflammation were related to the following factors: older patient age, larger retinal lesions, and extramacular location. In 30% of involved eyes, there was evidence of elevated IOP (despite use of glaucoma medications by some patients); other complications were uncommon. IOP of more than 21 mm Hg was associated with both increased AC cells and elevated flare (both P < or = .001) and with macular involvement (P = .009). Inflammation seemed to be more severe among patients in Brazil than among those at other sites.
CONCLUSIONS: There is substantial variation between patients in the severity of intraocular inflammation associated with ocular toxoplasmosis, attributable to multiple host- and disease-related factors. Results suggest that disease characteristics also vary in different areas of the world. Elevated IOP at initial examination reflects the severity of inflammation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027421     DOI: 10.1016/j.ajo.2008.09.006

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  25 in total

1.  Clinical pattern of ocular toxoplasmosis treated in a referral centre in Serbia.

Authors:  D Kovačević-Pavićević; A Radosavljević; A Ilić; I Kovačević; O Djurković-Djaković
Journal:  Eye (Lond)       Date:  2012-02-24       Impact factor: 3.775

2.  Real-time polymerase chain reaction and intraocular antibody production for the diagnosis of viral versus toxoplasmic infectious posterior uveitis.

Authors:  Marie-Hélène Errera; Pablo Goldschmidt; Laurence Batellier; Sandrine Degorge; Emmanuel Héron; Laurent Laroche; José-Alain Sahel; Mark Westcott; Christine Chaumeil
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-07-06       Impact factor: 3.117

3.  Clinical manifestation and prognosis of active ocular toxoplasmosis in Iran.

Authors:  Farzan Kianersi; Afsaneh Naderi Beni; Zahra Naderi Beni
Journal:  Int Ophthalmol       Date:  2012-06-26       Impact factor: 2.031

4.  Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial.

Authors:  Nader Baharivand; Ali Mahdavifard; Rohollah Fadaei Fouladi
Journal:  Int Ophthalmol       Date:  2012-09-28       Impact factor: 2.031

5.  Ocular cytokinome is linked to clinical characteristics in ocular toxoplasmosis.

Authors:  Alejandra de-la-Torre; Alexander W Pfaff; Michael E Grigg; Odile Villard; Ermanno Candolfi; Jorge E Gomez-Marin
Journal:  Cytokine       Date:  2014-04-16       Impact factor: 3.861

6.  Ocular toxoplasmosis in Iran: 40 cases analysis.

Authors:  Seidali Tabatabaei; Mohammad Soleimani; Alireza Foroutan; Mehdinili Ahmadabadi; Reza Zarei; Nilofar Piri; Arzhang Gordiz
Journal:  Int J Ophthalmol       Date:  2011-04-18       Impact factor: 1.779

Review 7.  Ocular toxoplasmosis II: clinical features, pathology and management.

Authors:  Nicholas J Butler; João M Furtado; Kevin L Winthrop; Justine R Smith
Journal:  Clin Exp Ophthalmol       Date:  2012-09-17       Impact factor: 4.207

Review 8.  Sitting at the window to the world--ocular parasites.

Authors:  Talin Barisani-Asenbauer
Journal:  Wien Med Wochenschr       Date:  2014-10-31

Review 9.  Corticosteroids as adjuvant therapy for ocular toxoplasmosis.

Authors:  Smitha Jasper; Satyanarayana S Vedula; Sheeja S John; Saban Horo; Yasir J Sepah; Quan Dong Nguyen
Journal:  Cochrane Database Syst Rev       Date:  2017-01-26

10.  Assessment of ocular toxoplasmosis patients reported at a tertiary center in the northeast of Iran.

Authors:  Seyedeh Maryam Hosseini; Elham Moghaddas; Karim Sharifi; Malihe Dadgar Moghaddam; Seyed Aliakbar Shamsian
Journal:  Int Ophthalmol       Date:  2018-01-15       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.